Fig. 2From: A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinomaROC analysis of sensitivity and specificity for the five-DNA methylation signature in predicting the OS of patients in the validation dataset. The AUC was 0.715 (95% CI = 0.62–0.81) (P < 0.001)Back to article page